-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, new crown oral drugs have continued to welcome good news
Vaccine stocks and neutralizing antibody concept stocks once again fell across the board following the positive development of oral drugs
.
New crown vaccine stock leaders Moderna and BioNTech both saw their biggest declines today by more than 24%, while Curevac and Novavax fell by about 8% and 12%, respectively
.
Neutralizing antibody stock Vir Biotechnology fell 15%, Regeneron fell 6%, and Eli Lilly, which also owns New Crown Neutral, also fell 3%
.
Vaccine stocks share price changes in the past 5 days
Moderna is the vaccine stock that has suffered the most recently
.
On Thursday, Moderna's third quarterly report announced that due to capacity constraints, its vaccines only achieved sales of 4.
8 billion U.
S.
dollars.
The annual production capacity and sales expectations were both lowered, which immediately caused a nearly 20% share price drop
.
The next day, following the announcement of Pfizer's new crown oral drug data, it fell by nearly 20%.
In the past two days, it has fallen by nearly 40%, and its market value has evaporated by nearly 50 billion
.
With turbulence on the new crown track, Pfizer has undoubtedly become a true leader, achieving dual coverage of vaccines and oral drugs .
The third-quarter report released on Tuesday showed that the company’s mRNA vaccine cooperation with BioNTech achieved quarterly sales of 13 billion U.
S.
dollars, and annual sales are expected to reach 36 billion U.
S.
dollars; now oral drugs have obtained clinical data significantly better than Merck’s, and even comparable to those in China.
And antibodies .
According to industry insiders, the follow-up market for vaccines is still broad, while neutralizing antibodies are limited.
Pfizer's data can be regarded as a dimensional reduction blow for neutralizing antibodies .
From: Pfizer official website
Vaccine stocks and neutralizing antibody concept stocks once again fell across the board following the positive development of oral drugs
.
New crown vaccine stock leaders Moderna and BioNTech both saw their biggest declines today by more than 24%, while Curevac and Novavax fell by about 8% and 12%, respectively
.
Neutralizing antibody stock Vir Biotechnology fell 15%, Regeneron fell 6%, and Eli Lilly, which also owns New Crown Neutral, also fell 3%
.
Vaccine stocks share price changes in the past 5 days
Moderna is the vaccine stock that has suffered the most recently
.
On Thursday, Moderna's third quarterly report announced that due to capacity constraints, its vaccines only achieved sales of 4.
8 billion U.
S.
dollars.
The annual production capacity and sales expectations were both lowered, which immediately caused a nearly 20% share price drop
.
The next day, following the announcement of Pfizer's new crown oral drug data, it fell by nearly 20%.
In the past two days, it has fallen by nearly 40%, and its market value has evaporated by nearly 50 billion
.
With turbulence on the new crown track, Pfizer has undoubtedly become a true leader, achieving dual coverage of vaccines and oral drugs .
The third-quarter report released on Tuesday showed that the company’s mRNA vaccine cooperation with BioNTech achieved quarterly sales of 13 billion U.
S.
dollars, and annual sales are expected to reach 36 billion U.
S.
dollars; now oral drugs have obtained clinical data significantly better than Merck’s, and even comparable to those in China.
And antibodies .
According to industry insiders, the follow-up market for vaccines is still broad, while neutralizing antibodies are limited.
Pfizer's data can be regarded as a dimensional reduction blow for neutralizing antibodies .
